NO752192L - - Google Patents
Info
- Publication number
- NO752192L NO752192L NO752192A NO752192A NO752192L NO 752192 L NO752192 L NO 752192L NO 752192 A NO752192 A NO 752192A NO 752192 A NO752192 A NO 752192A NO 752192 L NO752192 L NO 752192L
- Authority
- NO
- Norway
- Prior art keywords
- mol
- acid
- solution
- water
- stirred
- Prior art date
Links
- 239000002253 acid Substances 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 20
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000000725 suspension Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000000155 melt Substances 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- -1 alkali metal salts Chemical class 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 2
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- GEDFWVDKXAESRN-LSWJPFSZSA-N sld 105 Chemical compound O=C([C@@H]1N2C3=C(C4=CC=CC=C42)CCN2CCC[C@]([C@@H]32)(C1)CC)NC1CC1 GEDFWVDKXAESRN-LSWJPFSZSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- JMORAWFVNMGOKQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O JMORAWFVNMGOKQ-MGMRMFRLSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229950006936 apovincamine Drugs 0.000 description 1
- OZDNDGXASTWERN-UHFFFAOYSA-N apovincamine Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)C=C(C(=O)OC)N5C2=C1 OZDNDGXASTWERN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
- WXQJMUQRXNZZFY-POAQFYNOSA-N deoxyvincaminamide Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@H](C(N)=O)N5C2=C1 WXQJMUQRXNZZFY-POAQFYNOSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D461/00—Heterocyclic compounds containing indolo [3,2,1-d,e] pyrido [3,2,1,j] [1,5]-naphthyridine ring systems, e.g. vincamine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7432095A FR2285880A1 (fr) | 1974-09-24 | 1974-09-24 | Nouvel amide, ses sels, sa preparation et les medicaments qui en contiennent |
| FR7516290A FR2312245A1 (fr) | 1975-05-26 | 1975-05-26 | Nouveaux apovincamides, leurs sels, leur preparation et les medicaments qui en contiennent |
| FR7517670A FR2313056A1 (fr) | 1975-06-06 | 1975-06-06 | Nouvel amide, ses sels, sa preparation et les medicaments qui en contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO752192L true NO752192L (da) | 1976-03-25 |
Family
ID=27250361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO752192A NO752192L (da) | 1974-09-24 | 1975-06-19 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US4011330A (da) |
| JP (1) | JPS5139699A (da) |
| CA (1) | CA1031344A (da) |
| CH (1) | CH603651A5 (da) |
| DE (1) | DE2528609C3 (da) |
| DK (1) | DK138427B (da) |
| ES (1) | ES438799A1 (da) |
| FI (1) | FI751840A (da) |
| GB (1) | GB1460235A (da) |
| IE (1) | IE41260B1 (da) |
| IL (1) | IL47590A (da) |
| LU (1) | LU72792A1 (da) |
| NL (1) | NL7508740A (da) |
| NO (1) | NO752192L (da) |
| SE (1) | SE7507088L (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU171663B (hu) * | 1975-09-01 | 1978-02-28 | Richter Gedeon Vegyeszet | Sposob poluchenija novykh proizvodnykh 14-skobka-zamehhennogo metil-skobka zakryta-vinkana |
| GB1550496A (en) * | 1976-12-31 | 1979-08-15 | Logeais Labor Jacques | 1,2,3,3a4,5-hexahydro-canthine derivatives a process for their preparation and their therapeutic applications |
| FR2407931A1 (fr) * | 1977-11-02 | 1979-06-01 | Synthelabo | Derives de l'eburnamenine et leur application en therapeutique |
| HU187733B (en) * | 1982-06-30 | 1986-02-28 | Richter Gedeon Vegyeszeti Gyar Rt,Hu | Process for preparing apovincaminic acid derivatives |
| HU191938B (en) * | 1984-07-11 | 1987-04-28 | Andras Vedres | Process for production of new derivatives of 9 and 11 nitro-apovincamin acid |
| JPH0349630Y2 (da) * | 1985-09-12 | 1991-10-23 | ||
| FR2869034B1 (fr) * | 2004-04-14 | 2008-04-04 | Biocortech Soc Par Actions Sim | Derive du 14,15-dihydro 20,21-dinoreburnamenin 14-ol et leur utilisation pour le traitement des depressions |
| US10092550B2 (en) | 2014-10-21 | 2018-10-09 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof |
| US9907786B2 (en) | 2014-10-21 | 2018-03-06 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2176516B1 (da) * | 1972-03-22 | 1975-03-14 | Synthelabo |
-
1975
- 1975-05-19 FI FI751840*A patent/FI751840A/fi not_active Application Discontinuation
- 1975-06-19 DK DK277975AA patent/DK138427B/da unknown
- 1975-06-19 SE SE7507088A patent/SE7507088L/xx unknown
- 1975-06-19 NO NO752192A patent/NO752192L/no unknown
- 1975-06-23 IE IE1391/75A patent/IE41260B1/xx unknown
- 1975-06-23 US US05/589,088 patent/US4011330A/en not_active Expired - Lifetime
- 1975-06-23 ES ES75438799A patent/ES438799A1/es not_active Expired
- 1975-06-24 CH CH818075A patent/CH603651A5/xx not_active IP Right Cessation
- 1975-06-24 LU LU72792A patent/LU72792A1/xx unknown
- 1975-06-26 CA CA230,244A patent/CA1031344A/en not_active Expired
- 1975-06-26 DE DE2528609A patent/DE2528609C3/de not_active Expired
- 1975-06-27 JP JP50079923A patent/JPS5139699A/ja active Pending
- 1975-06-27 IL IL47590A patent/IL47590A/xx unknown
- 1975-06-27 GB GB2736975A patent/GB1460235A/en not_active Expired
- 1975-07-22 NL NL7508740A patent/NL7508740A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU8257175A (en) | 1977-01-06 |
| NL7508740A (nl) | 1976-03-26 |
| JPS5139699A (en) | 1976-04-02 |
| ES438799A1 (es) | 1977-03-16 |
| CH603651A5 (da) | 1978-08-31 |
| SE7507088L (sv) | 1976-03-25 |
| CA1031344A (en) | 1978-05-16 |
| DE2528609C3 (de) | 1978-06-01 |
| GB1460235A (en) | 1976-12-31 |
| IE41260L (en) | 1976-03-24 |
| DK138427B (da) | 1978-09-04 |
| DE2528609B2 (de) | 1977-10-13 |
| DK138427C (da) | 1979-02-12 |
| DE2528609A1 (de) | 1976-04-01 |
| IL47590A (en) | 1978-10-31 |
| LU72792A1 (da) | 1976-04-13 |
| US4011330A (en) | 1977-03-08 |
| DK277975A (da) | 1976-03-25 |
| IE41260B1 (en) | 1979-11-21 |
| FI751840A (da) | 1976-03-25 |
| IL47590A0 (en) | 1975-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4826838A (en) | Analgesic carbocyclic and heterocyclic carbonylmethylene-and carbonylmethypipidines and-pyrrolidines | |
| JPH05320162A (ja) | ペプチド性キヌクリジン | |
| EA005206B1 (ru) | Бициклические аминокислоты в качестве фармацевтических агентов | |
| NO752192L (da) | ||
| SU1308196A3 (ru) | Способ получени 5,11-дигидро-11- @ (1-метил-4-пиперидинил)-амино @ -карбонил @ -6 @ -дибенз ( @ , @ )азепин-6-она или его солей | |
| WO1994012497A1 (en) | Heterocyclic compound | |
| US4855422A (en) | Process for the preparation of azoniaspironortropanol esters | |
| JPH02167279A (ja) | アポビンカミン酸誘導体 | |
| DE2724501A1 (de) | Neue, in 11-stellung substituierte 5,11-dihydro-6h-pyrido eckige klammer auf 2,3-b eckige klammer zu eckige klammer auf 1,4 eckige klammer zu benzodiazepin-6- one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| JPS6031833B2 (ja) | 新規な２０，２１↓−ジノルエブルナメニン誘導体、その製造法及び製薬組成物 | |
| KR100339115B1 (ko) | 결정성3-(4-헥실옥시-1,2,5-티아디아졸-3-일)-1,2,5,6-테트라하이드로-1-메틸피리딘(+)l-하이드로겐타르트레이트,이의제조방법및이를포함하는약제학적조성물 | |
| JPH045289A (ja) | アミド化合物 | |
| JP5291721B2 (ja) | 置換３−ヒドロキシピリジン及びその医薬組成物 | |
| CH637118A5 (de) | Verfahren zur herstellung neuer phenylazacycloalkane. | |
| DE69015208T2 (de) | Glutamin- und asparginsäurederivate mit antigastrinwirkung und verfahren zu deren herstellung. | |
| DK142200B (da) | Analogifremgangsmåde til fremstilling af 14-substituerede vincanderivater eller syreadditionssalte eller kvaternære salte deraf. | |
| JPH04368359A (ja) | カプサイシン誘導体又はその酸エステルを有効成分とする鎮痛剤、血管拡張剤 | |
| JPS6116272B2 (da) | ||
| EP0101633B1 (en) | Pyridinecarboxylic esters of dopamine and of its n-alkyl derivatives | |
| DE69018741T2 (de) | Konjugierte gamma-Hydroxybutenolid-Derivate und sie als aktiver Wirkstoff enthaltende Mittel gegen Magengeschwüre. | |
| WO1999062865A1 (en) | Haloethyl-2-[ (2,6-dichlorophenyl) amino] phenylacetoxyacetate derivatives and their use as an intermediate to synthesize aceclofenac | |
| JP4732454B2 (ja) | 抗糖尿病性および抗炎症性を有するコロソリン酸の新規構造類似体 | |
| JPS5838283A (ja) | ビンカミン誘導体、その製造法およびそれを有効成分とする脳塞栓症治療剤 | |
| RU2067979C1 (ru) | Производное аминобензойной кислоты или его фармацевтически приемлемая соль | |
| DE2125588A1 (de) | Verfahren zur Herstellung neuer heterocyclischer Verbindungen |